Design Therapeutics Inc Stock
Design Therapeutics Inc Stock price
Key metrics
| Market capitalization | $340.86m |
| Enterprise Value | $89.31m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 1.35 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-60.81m |
| Free Cash Flow (TTM) Free Cash Flow | $-46.41m |
| Cash position | $254.07m |
Is Design Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Design Therapeutics Inc Stock Analysis
Analyst Opinions
3 Analysts have issued a Design Therapeutics Inc forecast:
Analyst Opinions
3 Analysts have issued a Design Therapeutics Inc forecast:
Financial data from Design Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.59 -0.59 |
7%
7%
|
|
| EBITDA | -60 -60 |
26%
26%
|
EBIT (Operating Income) EBIT | -61 -61 |
26%
26%
|
| Net Profit | -48 -48 |
34%
34%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Design Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Design Therapeutics Inc Stock News
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.
| Head office | United States |
| CEO | Pratik Shah |
| Employees | 124 |
| Founded | 2017 |
| Website | www.designtx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
